Boehringer Ingelheim Reports the Commercial Availability of Cyltezo, an Interchangeable Biosimilar to Humira
Shots:
- The company launch Cyltezo, a US FDA-approved interchangeable biosimilar to Humira in the US for multiple chronic inflammatory diseases. Cyltezo is available as a prefilled syringe or an autoinjector pen
- The efficacy & safety of Cyltezo were based on the P-III randomized (VOLTAIRE-X) trial evaluating the effect of multiple switches b/w Humira & Cyltezo vs continuous treatment with Humira. The results showed PK equivalence with highly similar efficacy & immunogenicity, and comparable safety was observed in patients who received Humira continuously or who switched b/w Humira & Cyltezo
- Cyltezo was approved as a biosimilar in 2017 for multiple chronic inflammatory diseases & was approved as an interchangeable biosimilar in 2021
Ref: PR Newswire | Image: Boehringer Ingelheim
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
